{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-021235","form_type":"8-K","ticker":"TWST","cik":"0001581280","company_name":"Twist Bioscience Corp","filed_at":"2022-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.247635+00:00","generated_at":"2026-06-24T03:20:28.505250+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Twist Bioscience Q3 FY2022 revenue $56.1M (+60% YoY), raises FY guidance to $203M","bullets":["Revenue $56.1M (+60% YoY from $35.0M); orders $59.7M (+53% YoY).","Net loss $60.5M ($1.08/sh) vs $40.0M ($0.82/sh) in prior year.","Cash, cash equivalents and investments total $527.6M as of June 30, 2022.","FY2022 revenue guidance raised to $203M from prior outlook.","Launched Twist MRD Rapid 500 Panel, human monkeypox controls, and expanded EUA for SARS-CoV-2 NGS assay."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-021235","json":"https://secwatch.observer/filing/0001628280-22-021235.json","markdown":"https://secwatch.observer/filing/0001628280-22-021235.md","text":"https://secwatch.observer/filing/0001628280-22-021235.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1581280/000162828022021235/0001628280-22-021235-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1581280/000162828022021235/twist-20220805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T03:20:28.505250+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}